Bayer Aktiengesellschaft (ETR:BAYN)

Market Cap	47.76B +73.1%
Revenue (ttm)	45.38B -1.7%
Net Income	-1.74B
EPS	-1.77
Shares Out	982.42M
PE Ratio	n/a
Forward PE	10.45
Dividend	0.11 (0.22%)
Ex-Dividend Date	Apr 27, 2026

Volume	178,049
Open	48.50
Previous Close	48.61
Day's Range	47.90 - 48.50
52-Week Range	25.78 - 53.92
Beta	0.83
Analysts	Buy
Price Target	56.83 (+18.4%)
Earnings Date	Aug 4, 2026

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1863
• Employees: 87,830
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: BAYN

Financial Performance

In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.

Analyst Summary

According to 18 analysts, the average rating for BAYN stock is "Buy." The 12-month stock price target is €56.83, which is an increase of 18.40% from the latest price.

Price Target

€56.83

(18.40% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 21, 2026

Data Sources Report a data error